Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer
Cancer Chemotherapy and Pharmacology, 06/08/2012
Clinical Article
Kentepozidis N et al. – The biweekly administration of paclitaxel/carboplatin regimen in patients with castration–resistant prostate cancer is an active and well–tolerated regimen which merits to be further evaluated in the context of salvage treatment.



